Prospective randomized human trials, crossover pharmacokinetic studies, and ClinicalTrials.gov interventional readouts with direct participant sample sizes (N). Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Future research needs to determine whether the addition of biomarkers to clinical and sociodemographic variables can improve model accuracy in predicting full symptom relief of pharmacologically-treated psychotic depression.
This analysis suggested greater reductions in bodyweight and HbA1c (%) levels associated with tirzepatide 10 and 15 mg than with semaglutide 2.4 mg in people with obesity or overweight and T2D.
Mapping from data-driven symptom improvement onto neural circuits revealed treatment-responsive neural profiles that may aid in optimal patient selection for future trials.
443 individuals expressed interest within eight months; 50 met the criteria for enrollment.
Incidence of total side effects was lower in the combination groups than in the high-intensity rosuvastatin group (p = 0.048).
Sex was an effect.
Purine-related metabolites were decreased across all arms.
We conclude that semaglutide improves blood sugar control with automated insulin delivery compared to placebo.
One patient (treatment) experienced contact dermatitis.
Of 1761 participants screened, 1268 were enrolled (median [IQR] age, 54 [45-65] years; 914 female [72%]), with 505 in the single-drug treatment cohort, 510 in the 2-pill cohort, and 253 in the 3-pill cohort.
Forty-eight participants (34 [71%] female; mean [SD] age, 39.9 [10.6] years) were randomized.
The microneedling of 1% applied to the skin cetirizine proved efficient in promoting hair growth without problems in the treatment of male androgenetic hair loss.
Although adding ezetimibe to atorvastatin can decrease LDL and hs-CRP levels in short-term follow-up; it is not effective in lowering short-term major heart and blood vessel events in patients after PCI.
Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants with type 2 diabetes.
The long-term safety profile observed in the Semaglutide Effects on heart and blood vessel Outcomes in People with Overweight or Obesity (SELECT) study is consistent with previously reported semaglutide studies.
Improvement in insulin sensitivity was proportional to weight and fat loss, with greater strength of association with tirzepatide.
In 363 adult patients (225 from EMBARC and 138 from CANBIND-1; mean [SD] age, 36.6 [13.1] years; 235 women [64.7%]), the best-performing models using pretreatment clinical features and functional connectivity of the dorsal...
The bioavailability of semaglutide following oral and subcutaneous administrations has been determined using a validated bioanalytical method.
In older men with obesity and hypogonadism, adding TRT for 6 months to LT does not result in further improved cardiometabolic profiles and could potentially blunt some of the metabolic benefits induced by LT.
Semaglutide markedly improved sperm morphology, total testosterone levels and symptoms of hypogonadism.
These results support a relationship between semaglutide 2.4 mg treatment of overweight and obesity and reduced need for blood-pressure-lowering and lipid-lowering treatment, facilitating treatment intensity...
A clinically meaningful reduction in risk of chronic kidney disease progression was observed with semaglutide versus placebo regardless of.
The overall PK interaction between rosuvastatin and total ezetimibe was not significant.
In a population with mild-to-moderate high blood pressure, long-term therapy with GMRx2-based treatment achieved high levels of BP control and was well tolerated.Trial registration: NCT04518306.
In the absence of contraindications, pioglitazone/metformin FDC supplemented with dapagliflozin may serve as a safe and effective alternative to basal insulin combined with metformin for rectifying.
Fifty-two weeks of testosterone supplementation combined with progressive resistance training may enhance physical performance, alleviate fatigue, and had no notable detrimental impacts among males aged ≥70 suffering from...
Safety and tolerability of cotadutide 600 μg were comparable to semaglutide.
These results suggest that the greater blood sugar control observed for tirzepatide manifests as improved fasting glucose and glucose excursion control, due to improvements in ISR, insulin sensitivity, and glucagon suppression.
In these KEEPS Continuation analyses, there were no long-term cognitive effects of short-term exposure to mHT started in early menopause versus placebo.
The combination of applied to the skin finasteride 0.25% with minoxidil 5% provides superior efficacy in the treatment of male pattern androgenic hair loss compared to applied to the skin minoxidil 5% alone.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
